Validation and Utility of Drug-Nutrient Interaction and Dietary Supplement Mechanistic Activity in the Natural Medicines Database

Overview

Publisher Unknown

Date 2025 Jan 6

PMID 39758135

Authors

Blake O Langley

Eileen Rillamas-Sun

Yuhan Huang

Amy Indorf

Michael Robles

Rachel Feaster

Lia DAddario

Isaac J Ergas

Janise M Roh

Lawrence H Kushi

Heather Greenlee

Affiliations

Soon will be listed here.

Abstract

Purpose: The increasing use of dietary supplements by patients with cancer and other chronic diseases requires the systematized review of potential interactions between prescription drugs and nutrients from supplements by health care and clinical research teams. Dietary supplement interaction databases are positioned to fill a gap in quantifying potential risks for patients, although none have been assessed for reliability in data interpretation. The NatMed database, a source for comprehensive reports on mechanistic and safety data for dietary supplement ingredients, was evaluated for use in future investigations.

Methods: Data from NatMed were retrieved using licensed end points for ingredient monographs with drug-nutrient interactions with doxorubicin across five pharmacokinetic and metabolic pathways, and for ingredient monographs with antioxidant activity. Interactions between dietary supplements and doxorubicin treatment and antioxidant monographs were independently reviewed and characterized by clinical pharmacists. Cohen's K was used to measure interrater reliability and the degree of agreement between pharmacists.

Results: Three hundred fifteen potential interactions with doxorubicin (n = 115 monographs) and 455 other antioxidant ingredients were identified and reviewed by clinical pharmacists. There was substantial to near-perfect agreement for drug-nutrient interactions with doxorubicin (Cohen's K = 0.64-0.85) and for antioxidants (Cohen's K = 0.84). A small proportion of retrieved monographs were not validated by the clinical pharmacists for interactions with doxorubicin (n = 20 occurrences, 6.4%) or for antioxidant activity (n = 28, 6.2%).

Conclusion: A high degree of reliability in data on dietary supplement interactions with doxorubicin and mechanisms of action suggests NatMed may be a dependable source of data for future investigators. Additional procedures including independent data validation and use of multiple dietary supplement interaction databases will strengthen the quality of findings in future studies.

References

Ambrosone C, Zirpoli G, Hutson A, McCann W, McCann S, Barlow W . Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2019; 38(8):804-814. PMC: 7062457. DOI: 10.1200/JCO.19.01203. View

Mehta D, Gardiner P, Phillips R, McCarthy E . Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med. 2008; 14(10):1263-9. PMC: 2787410. DOI: 10.1089/acm.2008.0290. View

Frenkel M, Morse M, Narayanan S . Addressing Patient Requests to Add Dietary Supplements to Their Cancer Care-A Suggested Approach. Nutrients. 2023; 15(24). PMC: 10745580. DOI: 10.3390/nu15245029. View

Goey A, Mooiman K, Beijnen J, Schellens J, Meijerman I . Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev. 2013; 39(7):773-83. DOI: 10.1016/j.ctrv.2012.12.008. View

Lawenda B, Kelly K, Ladas E, Sagar S, Vickers A, Blumberg J . Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Inst. 2008; 100(11):773-83. DOI: 10.1093/jnci/djn148. View

Mishra S, Stierman B, Gahche J, Potischman N . Dietary Supplement Use Among Adults: United States, 2017-2018. NCHS Data Brief. 2021; (399):1-8. View

Sweeney S, Hamadeh H, Abrams N, Adam S, Brenner S, Connors D . Challenges to Using Big Data in Cancer. Cancer Res. 2023; 83(8):1175-1182. PMC: 10102837. DOI: 10.1158/0008-5472.CAN-22-1274. View

Asher G, Corbett A, Hawke R . Common Herbal Dietary Supplement-Drug Interactions. Am Fam Physician. 2017; 96(2):101-107. View

Du M, Luo H, Blumberg J, Rogers G, Chen F, Ruan M . Dietary Supplement Use among Adult Cancer Survivors in the United States. J Nutr. 2020; 150(6):1499-1508. PMC: 7269731. DOI: 10.1093/jn/nxaa040. View

10.

Quinney S . Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk. Clin Pharmacol Ther. 2019; 106(1):72-74. PMC: 6617974. DOI: 10.1002/cpt.1481. View

11.

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

12.

Cheung-Ong K, Giaever G, Nislow C . DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013; 20(5):648-59. DOI: 10.1016/j.chembiol.2013.04.007. View

13.

Block K, Koch A, Mead M, Tothy P, Newman R, Gyllenhaal C . Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008; 123(6):1227-39. DOI: 10.1002/ijc.23754. View

14.

Prescott J, Drake V, Stevens J . Medications and Micronutrients: Identifying Clinically Relevant Interactions and Addressing Nutritional Needs. J Pharm Technol. 2021; 34(5):216-230. PMC: 6109862. DOI: 10.1177/8755122518780742. View

15.

Haefeli W, Carls A . Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol. 2014; 10(3):359-77. DOI: 10.1517/17425255.2014.873786. View

16.

Vardell E . Natural Medicines: A Complementary and Alternative Medicines Tool Combining Natural Standard and the Natural Medicines Comprehensive Database. Med Ref Serv Q. 2015; 34(4):461-70. DOI: 10.1080/02763869.2015.1082382. View

17.

Jiang H, Zuo J, Li B, Chen R, Luo K, Xiang X . Drug-induced oxidative stress in cancer treatments: Angel or devil?. Redox Biol. 2023; 63:102754. PMC: 10220276. DOI: 10.1016/j.redox.2023.102754. View

18.

Velicer C, Ulrich C . Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008; 26(4):665-73. DOI: 10.1200/JCO.2007.13.5905. View

19.

Crake R, Strother M, Phillips E, Doogue M, Zhang M, Frampton C . Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study. Sci Rep. 2021; 11(1):5648. PMC: 7952716. DOI: 10.1038/s41598-021-85048-1. View

20.

Waghray D, Zhang Q . Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. J Med Chem. 2017; 61(12):5108-5121. PMC: 6281405. DOI: 10.1021/acs.jmedchem.7b01457. View